This resource published in the Frontiers in Neurology journal, examines the short-term impact of BoNT-A on spasticity and motor outcomes, and provides a qualitative synthesis of trial evidence across different dosing strategies, target limbs, and rehabilitation approaches.

Spasticity is a key motor impairment in children with cerebral palsy (CP), with substantial effects on functional abilities and quality of life. Botulinum toxin type A (BoNT-A) is widely used to manage spasticity; however, uncertainty remains regarding the magnitude, duration, and functional relevance of its effects across diverse clinical contexts.